Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14.05. | Immunovia AB: Immunovia Publishes Interim Report for January-March 2025 | 108 | GlobeNewswire (Europe) | January-March 2025• Net sales, which for the quarter only included royalties, amounted to 139 KSEK (156).• Net earnings were -57.8 MSEK (-2.9), as a result of unrealized exchange rate effects due to... ► Artikel lesen | |
02.04. | IMMUNOVIA AB: Immunovia publishes the Annual Report for 2024 | 1 | Cision News | ||
01.04. | IMMUNOVIA AB: The exercise period for warrants series TO 3 begins today | 2 | Cision News | ||
IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
27.03. | IMMUNOVIA AB: Immunovia announces determined exercise price for warrants series TO 3 | 2 | Cision News | ||
24.03. | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 169 | PR Newswire | LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results... ► Artikel lesen | |
24.03. | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 148 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic... ► Artikel lesen | |
21.03. | IMMUNOVIA AB: Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study | 2 | Cision News | ||
19.03. | Immunovia AB: Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test | 133 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation... ► Artikel lesen | |
03.03. | IMMUNOVIA AB: Immunovia's CLARITI study results selected for prestigious presentation at the world's largest gastroenterology conference | 1 | Cision News | ||
25.02. | Immunovia reports Q4 results | 2 | Seeking Alpha | ||
25.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2024 | 179 | PR Newswire | LUND, Sweden, Feb. 25, 2025 /PRNewswire/ --
October- December 2024
Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155).
... ► Artikel lesen | |
21.02. | Immunovia initiates search for a new CFO | 3 | Seeking Alpha | ||
21.02. | IMMUNOVIA AB: Immunovia initiates search for a new CFO to support commercialization in the USA | 3 | Cision News | ||
21.02. | IMMUNOVIA AB: Invitation to Immunovia's Q4 presentation | 2 | Cision News | ||
31.01. | Change in number of shares and votes in Immunovia AB (publ) | 262 | PR Newswire | LUND, Sweden, Jan. 31, 2025 /PRNewswire/ -- During January 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series... ► Artikel lesen | |
20.01. | Immunovia AB announces outcome of exercise of warrants series TO 2 | 340 | PR Newswire | LUND, Sweden, Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January... ► Artikel lesen | |
08.01. | Immunovia AB (Publ) presents Nomination Committee | 260 | PR Newswire | LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.... ► Artikel lesen | |
02.01. | The exercise period for warrants of series TO 2 beings today: Immunovia AB | 349 | PR Newswire | LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2... ► Artikel lesen | |
02.01. | IMMUNOVIA AB: The exercise period for warrants of series TO 2 beings today | 2 | Cision News | ||
28.12.24 | Immunovia AB: Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme | 873 | PR Newswire | LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TELADOC HEALTH | 7,160 | -0,28 % | Aktien-Trading 4 Dummies - 3 Aktien. 2 Experten. 0 Langeweile (Hims & Hers, Teladoc & XTI Aerospace) | ||
HIMS & HERS HEALTH | 42,410 | +0,43 % | Paukenschlag bei Novo Nordisk und Hims & Hers mit 35%-Crash: Müssen Sie die Aktien jetzt verkaufen? | Was für ein Absturz: Eine plötzlich aufgekündigte Partnerschaft zwischen Novo Nordisk und Hims & Hers sorgt am Montag für ein Kursbeben. Eine Aktie trifft es dabei besonders hart. Noch im April hatten... ► Artikel lesen | |
BECTON DICKINSON | 146,25 | +0,24 % | Becton, Dickinson and Company (BDX): A Bull Case Theory | ||
DEXCOM | 73,04 | -0,96 % | Dexcom-Aktie mit großen Kursgewinnen (72,4399 €) | Grund zur Freude haben Aktionäre von Dexcom : Der Titel steigt deutlich. Zu den Performancebesten des Tages gehört heute die Aktie von Dexcom mit einem Kursplus von 5,41 Prozent. Die Aktie notierte... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,745 | -2,49 % | Atossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline | ||
EVOFEM BIOSCIENCES | - | - | Windtree Therapeutics: Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel | Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of... ► Artikel lesen | |
RYMAN HEALTHCARE | 1,101 | +0,09 % | RYMAN HEALTHCARE LIMITED: Ongoing Disclosure Notice - Dean Hamilton | ||
CYTOSORBENTS | 1,028 | -0,19 % | Cytosorbents Corp: CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb-ATR | PRINCETON, N.J., June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update | Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment... ► Artikel lesen | |
SENSEONICS | 0,446 | +5,64 % | Senseonics lays out hopes for next-gen CGM commercial timelines | ||
STAAR SURGICAL | 14,335 | -0,80 % | STAAR Surgical Names Deborah Andrews CFO | WASHINGTON (dpa-AFX) - STAAR Surgical Company (STAA), on Wednesday announced that Deborah Andrews has been appointed Chief Financial Officer, effective June 25, 2025. Andrews has served as Interim... ► Artikel lesen | |
EKSO BIONICS | 3,400 | -4,76 % | XFRA 23E0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEKSO BIONICS. NEW... ► Artikel lesen | |
INTERPACE BIOSCIENCES | 0,720 | 0,00 % | Interpace Biosciences, Inc.: Effective May 2, 2025, Interpace Diagnostics Will No Longer Accept Specimens for PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk | Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace"... ► Artikel lesen | |
INSPIRE MEDICAL SYSTEMS | 114,05 | +0,88 % | Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook | Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire... ► Artikel lesen | |
SOLENO THERAPEUTICS | 73,50 | +3,38 % | Soleno reports new data on VYKAT XR for Prader-Willi syndrome |